Kaur G - Search Results

1

Editor's Note: Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator.

Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R. Kaur G, et al. Clin Cancer Res. 2024 May 1;30(9):1996. doi: 10.1158/1078-0432.CCR-24-0857. Clin Cancer Res. 2024. PMID: 38690595 No abstract available.

2

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.

Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R. Kaur G, et al. Clin Cancer Res. 2004 Jul 15;10(14):4813-21. doi: 10.1158/1078-0432.CCR-03-0795. Clin Cancer Res. 2004. PMID: 15269157

3

Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.

Burger AM, Kaur G, Hollingshead M, Fischer RT, Nagashima K, Malspeis L, Duncan KL, Sausville EA. Burger AM, et al. Among authors: kaur g. Clin Cancer Res. 1997 Mar;3(3):455-63. Clin Cancer Res. 1997. PMID: 9815705

4

Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation.

Hose C, Kaur G, Sausville EA, Monks A. Hose C, et al. Among authors: kaur g. Clin Cancer Res. 2005 Sep 1;11(17):6370-81. doi: 10.1158/1078-0432.CCR-05-0291. Clin Cancer Res. 2005. PMID: 16144942

5

"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.

Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA. Rybak SM, et al. Among authors: kaur g. Cancer Res. 2003 Jun 1;63(11):2812-9. Cancer Res. 2003. PMID: 12782586

6

Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.

Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, Sausville EA. Burger AM, et al. Among authors: kaur g. Cancer Res. 1995 Jul 1;55(13):2794-9. Cancer Res. 1995. PMID: 7796405

7

Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.

Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, Kaufmann SH. Svingen PA, et al. Among authors: kaur g. Clin Cancer Res. 2000 Jan;6(1):237-49. Clin Cancer Res. 2000. PMID: 10656455

8

Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells.

Kaur G, Sausville EA. Kaur G, et al. Anticancer Drugs. 1996 Nov;7(8):815-24. doi: 10.1097/00001813-199611000-00001. Anticancer Drugs. 1996. PMID: 8991184

9

Growth inhibition by cholera toxin of human lung carcinoma cell lines: correlation with GM1 ganglioside expression.

Kaur G, Viallet J, Laborda J, Blair O, Gazdar AF, Minna JD, Sausville EA. Kaur G, et al. Cancer Res. 1992 Jun 15;52(12):3340-6. Cancer Res. 1992. PMID: 1375868

10

Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells.

Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Seynaeve CM, et al. Among authors: kaur g. Cancer Res. 1993 May 1;53(9):2081-6. Cancer Res. 1993. PMID: 7683251

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,601 results

Search Page

Filters